WARNING:This product contains nicotine. Nicotine is an addictive chemical.
Store

Clinical trials have shown that CBD can significantly improve the symptoms of pet dog dermatitis

2020/07/27|Sealebia|Industry news

Recently, canpal animal therapeutics Limited (ASX: CP1), an Australian pet medical company, has published a clinical trial report on CBD pet nutrition. The report shows that CBD can significantly improve the symptoms of "atopic dermatitis" in pet dogs.

CBD improves the symptoms of dermatitis in pet dogs

Pet dog atopic dermatitis, also known as atopic dermatitis and hereditary allergic dermatitis, is a kind of pruritus skin disease and chronic skin disease occurring in many animals.

About 10% of dogs suffer from the disease. Atopic dermatitis is associated with genetic factors, immune dysfunction and pharmacological and physiological abnormalities.

CBD is cannabinoid in hemp leaves. Dermacann is a CBD pet health product developed by cannpal company, which is used to improve the skin health and immunity of pet dogs.

Cannpal conducted a 56 day randomized, double-blind, placebo-controlled clinical trial in 13 dogs to test the safety and efficacy of two different dermacan preparations in improving the "atopic dermatitis" of pet dogs.

During the trial, the researchers fed the dog twice a day with dermacann preparation. After 56 days, it was found that the cadesi-4 value, which measures the severity of atopic dermatitis, was significantly decreased in both groups (with an average reduction of 51%) in both "dermacan preparation 1" and "dermacan preparation 2", while the cadesi-4 value in the placebo control group was increased.

Note: DC-1 represents dermacann preparation 1, DC-2 represents dermacann preparation 2, and placebo is placebo control group. The lower the value of cadesi-4, the better the therapeutic effect.

During the course of the trial, there were no adverse reactions in dogs treated with dermacann preparation. Currently, cannpal is applying for a patent and is actively preparing to launch dermacan products in multiple markets.

"Dermacann will be the only clinically proven edible CBD pet nutrition for improving dog skin health," said cannpal, general manager of cannpal.

In addition to dermacann, cannpal has developed a cannabinoid product cpat-01, which is used to relieve pain and inflammation in pets. The main ingredients of this product are CBD (cannabinol) and THC (tetrahydrocannabinol).

CBD, which is extracted from the leaves of industrial hemp, is a "super ingredient" rising in recent two years. It is widely used in food, beverage, medicine, skin care products and other fields. The pet products derived from CBD are very popular in European and American markets.

According to the Research Report of new frontier data, the CBD pet products market is the fastest growing category in the CBD industry. In 2017, the total sales of CBD pet products in the United States reached 13 million US dollars, and it is expected to reach 125 million US dollars by 2022.

In 2019, remedy rebiew conducted a survey on 1020 American pet owners and found that 30% of pet owners had used CBD products for their pets. The reasons for using CBD products from high to low were joint pain, relieving anxiety and improving inflammatory pain. 94% of pet owners approved the effect of CBD on pets.

In summary, CBD is mainly used in the field of pet, mainly focusing on "functional food" and "pet medicine". The pet food containing CBD, such as biscuits, dried meat and canned food, can be used to improve pet anxiety, inflammation, pain, etc.; CBD has the potential to treat pet epilepsy, depression, osteoarthritis and other diseases, and can be used to develop drugs.


Contact us

Follow us